A cross sectional study of HPV type prevalence according to age and cytology

BMC Infectious Diseases

Efstathia Panotopoulou⁵  George Magiakos³  Ioanna Tsiaoussi⁵  Dimitra Daskalopoulou²  Issidora Papassideri⁴  Evangelia Myriokefalitaki⁵  Lina Michala¹  Elpida Tsimplaki⁵  Stefanos Papaspyridakos⁵  Elena Argyri⁵ 

[1]1st Department of Obstetrics and Gynaecology, University of Athens, ‘Alexandra’ Hospital, Alexandra, Greece

[2]Department of Cytopathology, Regional Anticancer Oncology Hospital of Athens "St. Savvas", 171 Alexandras Avenue, 11522, Athens, Greece

[3]1st Department of Gynaecology, Regional Anticancer Oncology Hospital of Athens "St. Savvas", 171 Alexandras Avenue, 11522, Athens, Greece

[4]Department of Cell Biology and Biophysics, Faculty of Biology, University of Athens, Panepistimiopolis, 15784, Athens, Greece

[5]Department of Virology, “G. Papanikolaou” Research Center of Oncology and Experimental Surgery, Regional Anticancer Oncology Hospital of Athens “St. Savvas”, 171 Alexandras Avenue, 11522, Athens, Greece

关键词: Cytology;    Age-distribution;    Typing;    Prevalence;    Human papillomavirus (HPV);   

Others  :  1158473
DOI  :  10.1186/1471-2334-13-53

 received in 2012-04-26, accepted in 2013-01-24,  发布年份 2013

【 摘 要 】

Background

A cross sectional study to investigate HPV prevalence according to age and cytology.

Methods

Women presenting to a gynaecological outpatient clinic for a Pap smear test were included in the study (n=3177). All women had cervical cytology and HPV testing.

Results

Overall prevalence of any 24 HPV type analysed was 33.1% (95% CI 31.5% to 34.7%) and HPV 16 and HPV 42 were the most frequent (6.7% (95% CI 5.8% to 7.6%), 6.8% (95% CI 5.9% to 7.6%)), in total samples. Multiple HPV infection rate was 12.9% (95% CI 11.8% to 14.1%). High risk HPV (hrHPV) types were present in 27.4% (95% CI 25.8% to 28.9%) of the samples.

HPV prevalence was highest among 14 to 19 y.o (46.6% (95% CI 40.7%-52.4%)) and second highest among 30–34 y.o. (39.7%, 95% CI 35.4%–44%). HPV 16 was highest among 20–24 (9.0% (95% CI 6.4%–11.6%)) and second highest among 50 to 54 y.o. (6.3% (95% CI 2.9% to 9.8%).

In Low-grade Squamous Intraepithelial Lesions (LgSIL) cytology samples, the most frequently detected hrHPV types were: 16 (14.5% (95% CI 12.1% to 16.9%)), 51 (13.0% (95% CI 10.7% to 15.3%)) and 53 (9.1% (95% CI 7.2% to 11.1%)) and in High-grade Squamous Intraepithelial Lesions (HgSIL) were: HPV 16 (37.2% (95% CI 26.5% to 47.9%)), HPV 51 (17.9% (95% CI 9.4% to 26.5%)) and HPV 18 (12.8% (95% CI 5.4% to 20.2%)).

Conclusions

In the population studied, HPV 16 and 51 were the most frequent detected hrHPV types. HPV positivity, hrHPV and multiple HPV types infections were higher in young women, while HPV prevalence declined with increasing age and presented two peaks a higher (14–19 y.o.) and a lower one (30–34 y.o.) These results may contribute to the creation of a national screening programme.

【 授权许可】

   
2013 Argyri et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
• [2]Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1157-1164.
• [3]Smith JS, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43(4 Suppl):5-25. S25.e1-41
• [4]Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202(12):1789-1799.
• [5]Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
• [6]Future II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):27-1915.
• [7]Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
• [8]Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G: HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006, 367(9518):55-1247.
• [9]Panotopoulou E, Tserkezoglou A, Kouvousi M, Tsiaousi I, Chatzieleftheriou G, Daskalopoulou D, Magiakos G: Prevalence of human papillomavirus types 6, 11, 16, 18, 31, and 33 in a cohort of Greek women. J Med Virol 2007, 79(12):1898-1899.
• [10]Agorastos T, Lambropoulos AF, Sotiriadis A, Mikos T, Togaridou E, Emmanouilides CJ: Prevalence and distribution of high-risk human papillomavirus in Greece. Eur J Cancer Prev 2009.
• [11]Papachristou E, Sypsa V, Paraskevis D, Gkekas A, Politi E, Nicolaidou E, Anifantis I, Psichogiou M, Tsitsika A, Hadjivassiliou M, Petrikkos G, Katsambas A, Creatsas G, Hatzakis A: Prevalence of different HPV types and estimation of prognostic risk factors based on the linear array HPV genotyping test. J Med Virol 2009, 81(12):2059-65.
• [12]Stamataki P, Papazafiropoulou A, Elefsiniotis I, Giannakopoulou M, Brokalaki H, Apostolopoulou E, Sarafis P, Saroglou G: Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. BMC Infect Dis 2010, 15:10-27.
• [13]Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111(2):278-85.
• [14]Practice ACOG: Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 2009, 114(6):1409-1420.
• [15]Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme, second edition. NHSCSP Publication; 2010. http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.pdf webcite
• [16]Coupe VMH, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ: Age dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008, 98:646-651.
• [17]Burd E: Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003, 16:1-17.
• [18]De Sanjose S: Human Papillomavirus and Cancer. Epidemiology and prevention. 4th Monograph of the Spanish Society of Epidemiology 2006, 143-147.
• [19]Manhart LE, Holmes KK, Koutsky LA, Wood TR, Kenney DL, Feng Q, Kiviat NB: Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 2006, 33:502-508.
• [20]Ethier KA, Kershaw T, Niccolai L, Lewis JB, Ickovics JR: Adolescent women underestimate their susceptibility to sexually transmitted infections. Sex Transm Infect 2003, 79(5):408-411.
• [21]Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S: Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010, 116:1373-80.
• [22]Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007, 197:346-55.
• [23]Giorgi Rossi P, Bisanzi S, Paganini I, Di Iasi A, Angeloni C, Scalisi A, Macis R, Pini MT, Chini F, Carozzi FM, HPV Prevalence Italian Working Group: Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect Dis 2010, 10:214.
• [24]Pista A, de Oliveira CF, Cunha MJ, Paixao MT, Real O, CLEOPATRE Portugal Study Group: Prevalence of human Papillomavirus infection in women in Portugal: The CLEOPATRE Portugal study. Int J Gynecol Cancer 2011, 6:1150-1158.
• [25]Doménech-Peris A, Conesa-Zamora P, Sahuquillo-Frias L, Ortiz-Reina S, Moya-Biosca J, Acosta-Ortega J, Pérez-Guillermo M, Egea-Cortines M: Human papillomavirus genotyping in histological sections of precursor lesions of cervical carcinoma: its role as a possible adjunct for the evaluation of the oncogenic potential of specific human papillomavirus genotypes - a study in a coastal region of southeastern Spain. Gynecol Obstet Invest 2010, 70(2):113-9.
• [26]de Oña M, Alvarez-Argüelles ME, Torrents M, Villa L, Rodriguez-Feijoo A, Palacio A, Boga JA, Tamargo A, Melón S: Prevalence, evolution, and features of infection with human papillomavirus: a 15-year longitudinal study of routine screening of a women population in the north of Spain. J Med Virol 2010, 82(4):597-604.